AbbVie targets tau again in Voyager Alzheimer's tie-up
Developing an effective new treatment for Alzheimer’s disease has become the Mount Everest of pharma, with ambitious companies setting off into clinical trials with the best of intentions but unable to reach the summit of late-stage success.
Despite the setbacks and lost billions, biopharma is not giving up, as evidenced by the US drugmaker AbbVie’s (NYSE: ABBV) latest investment into a research collaboration with the clinical stage gene therapy company Voyager Therapeutics (Nasdaq: VYGR).
The collaboration will include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau, the protein that some drug developers are targeting as the potential cause of Alzheimer’s and other neurodegenerative diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze